Effects of Pegvisomant and Pasireotide LAR on vertebral fractures in acromegaly resistant to First-Generation SRLs.
Osteopathy is an emerging complication of acromegaly. In somatostatin receptor ligands (SRL)-resistant patients, Pegvisomant (PegV) and Pasireotide LAR (Pasi) are used for acromegaly treatment, but their effect on skeletal health is still not defined. In a longitudinal retrospective international study, we evaluated incidence of radiological vertebral fractures (VFs) in 55 pts with acromegaly resistant to first-generation SRL. At study entry, prevalent VFs occurred in 23 patients (41.8%). Biochemical acromegaly control was reached in 66.7% of patients on PegV and in 66.7% of patients on Pasi. During the follow-up, incident VFs (iVFs) were detected in 16 patients (29.1%). Occurrence of iVFs was associated with prevalent VFs (p=0.002), persistence of active acromegaly (p=0.01) and higher value of IGF-I during follow-up (p=0.03). Among patients with active disease at last visit, iVFs occurred less frequently in patients on treatment with Pasi (25%) compared to PegV (77.8% p=0.04), independently of the IGF-I values (p=0.9). In patients who reached biochemical control, 22.7% on Peg-V and 12.5% on Pasi had iVFs (p=0.4). Among both treatment groups, the presence of pre-existent VFs was the main determinant for iVFs. Our data show for the first time that patients with biochemically active disease treated with Pasi had lower risk of iVFs vs those treated with PegV . It also confirms that the presence of pre-existent VFs was the main determinant for iVFs. Additional studies on larger populations and with longer follow-up are needed to confirm our data and disclose the mechanisms underlying our findings.